Home » FDA Approves Titan’s Opioid Dependency Combination Therapy
FDA Approves Titan’s Opioid Dependency Combination Therapy
The FDA has approved Titan Pharmaceuticals’ combination therapy Probuphine for the treatment of opioid dependence.
A buprenorphine implant, Probuphine is designed to provide a constant, low dose of the drug for six months in patients who already take low-to-moderate doses of buprenorphine.
In a clinical study, 63 percent of patients treated with Probuphine had no evidence of illicit opioid use throughout the six months of treatment. Buprenorphine was previously approved only as a pill or a film placed under the tongue or inside of the cheek.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May